数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
David B. Weiner 董事 61 71.69万(USD) 未持股 2017-03-17
George W. Bickerstaff 董事 61 未披露 未持股 2017-03-17
Simon X. Benito 董事 72 22.78万(USD) 未持股 2017-03-17
Avtar Dhillon Chairman of the Board of Directors 56 24.08万(USD) 未持股 2017-03-17
J. Joseph Kim President, Chief Executive Officer and Director 48 297.36万(USD) 未持股 2017-03-17
Morton Collins 董事 81 22.58万(USD) 未持股 2017-03-17
Adel A. F. Mahmoud 董事 75 20.78万(USD) 未持股 2017-03-17
Angel Cabrera 董事 49 21.58万(USD) 未持股 2017-03-17

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
J. Joseph Kim President, Chief Executive Officer and Director 48 297.36万(USD) 未持股 2017-03-17
Peter D. Kies Chief Financial Officer 53 135.57万(USD) 未持股 2017-03-17
Niranjan Y. Sardesai Chief Operating Officer 49 139.28万(USD) 未持股 2017-03-17
Mark L. Bagarazzi Chief Medical Officer 56 139.38万(USD) 未持股 2017-03-17

董事简历

中英对照 |  中文 |  英文
David B. Weiner

David B. Weiner,于2016年3月加入我们的董事会。 Weiner博士最近加入了The Wistar Institute,该研究所是美国第一个独立的生物医学研究所,NCI指定的癌症中心,以及癌症,免疫学和传染病研究领域的国际领导者,担任其疫苗中心的执行副总裁和董事,癌症研究W. W. Smith Charitable Trust 赋予的教授。以前,Weiner博士是University of Pennsylvania病理和实验室医学教授,和University’s Perelman School of Medicine基因治疗和疫苗计划的主席。在科学界,Weiner博士被称为“DNA疫苗之父”。他在科学杂志上有350多篇同行评议的出版物,包括科学美国人等主流科学期刊,并被科学信息研究所指定为世界上被引用最多的科学家之一。 Weiner博士是拥有超过100项已颁发和未决的美国专利的发明家,Weiner博士获得了众多荣誉,包括2011年美国科学促进协会和2012年国际疫苗学会的研究员。他是NIH Director’s Transformative Research的获得者,2015年在世界疫苗大会上获得最佳学术研究小组的疫苗行业卓越奖。 Weiner博士于2015年在 Children’s Hospital of Philadelphia Grand Rounds 大会上被授予著名的Hilleman讲师职务,并获得了Abramson Cancer Center颁发的“ Stone Family奖”,他为癌症免疫治疗的DNA疫苗开创性的工作。 Weiner博士拥有University of Cincinnati College of Medicine发展生物学的博士学位,University of Cincinnati.生物学的理科硕士学位和B位于纽约Stony Brook的SUNY生物学理学士学位。


David B. Weiner joined The Wistar Institute in 2016 the nation’s first independent biomedical research institute, NCI-designated Cancer Center, and an international leader in cancer, immunology and infectious disease research, as Executive Vice President, Director of its Vaccine Center, and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research. Previously, Dr. Weiner was Professor of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine. In scientific circles, Dr. Weiner is known as the “father of DNA vaccines.” He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world. An inventor of more than 100 issued and pending US patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy. Dr. Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati. and a B.S. in biology from SUNY at Stony Brook in Stony Brook, N.Y.
David B. Weiner,于2016年3月加入我们的董事会。 Weiner博士最近加入了The Wistar Institute,该研究所是美国第一个独立的生物医学研究所,NCI指定的癌症中心,以及癌症,免疫学和传染病研究领域的国际领导者,担任其疫苗中心的执行副总裁和董事,癌症研究W. W. Smith Charitable Trust 赋予的教授。以前,Weiner博士是University of Pennsylvania病理和实验室医学教授,和University’s Perelman School of Medicine基因治疗和疫苗计划的主席。在科学界,Weiner博士被称为“DNA疫苗之父”。他在科学杂志上有350多篇同行评议的出版物,包括科学美国人等主流科学期刊,并被科学信息研究所指定为世界上被引用最多的科学家之一。 Weiner博士是拥有超过100项已颁发和未决的美国专利的发明家,Weiner博士获得了众多荣誉,包括2011年美国科学促进协会和2012年国际疫苗学会的研究员。他是NIH Director’s Transformative Research的获得者,2015年在世界疫苗大会上获得最佳学术研究小组的疫苗行业卓越奖。 Weiner博士于2015年在 Children’s Hospital of Philadelphia Grand Rounds 大会上被授予著名的Hilleman讲师职务,并获得了Abramson Cancer Center颁发的“ Stone Family奖”,他为癌症免疫治疗的DNA疫苗开创性的工作。 Weiner博士拥有University of Cincinnati College of Medicine发展生物学的博士学位,University of Cincinnati.生物学的理科硕士学位和B位于纽约Stony Brook的SUNY生物学理学士学位。
David B. Weiner joined The Wistar Institute in 2016 the nation’s first independent biomedical research institute, NCI-designated Cancer Center, and an international leader in cancer, immunology and infectious disease research, as Executive Vice President, Director of its Vaccine Center, and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research. Previously, Dr. Weiner was Professor of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine. In scientific circles, Dr. Weiner is known as the “father of DNA vaccines.” He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world. An inventor of more than 100 issued and pending US patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy. Dr. Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati. and a B.S. in biology from SUNY at Stony Brook in Stony Brook, N.Y.
George W. Bickerstaff
暂无中文简介

George W. Bickerstaff joined our Board effective March 21 2017.Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. Mr. Bickerstaff is currently a partner and the managing director of M.M. Dillon & Co., a healthcare and technology investment bank that he co-founded in 2005. In this role, he has advised dozens of companies on business strategy and financial and capital market issues. He has served Novartis Pharma AG as its chief financial officer from 2000 to 2005 and held senior financial positions at IMS Health from 1989 to 1997 and previously held financial positions with Dun & Bradstreet and General Electric. He currently serves as a member of the boards of directors of the following companies: ARIAD Pharmaceuticals, Inc. NasdaqGS: ARIA; Cardax, Inc. OTCQB: CDXI; and CareDx, Inc. (NASDAQ: CDNA). He holds a B.S. in Engineering and B.A. in Business Administration from Rutgers University and continued his executive education at Harvard Business School.
暂无中文简介
George W. Bickerstaff joined our Board effective March 21 2017.Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. Mr. Bickerstaff is currently a partner and the managing director of M.M. Dillon & Co., a healthcare and technology investment bank that he co-founded in 2005. In this role, he has advised dozens of companies on business strategy and financial and capital market issues. He has served Novartis Pharma AG as its chief financial officer from 2000 to 2005 and held senior financial positions at IMS Health from 1989 to 1997 and previously held financial positions with Dun & Bradstreet and General Electric. He currently serves as a member of the boards of directors of the following companies: ARIAD Pharmaceuticals, Inc. NasdaqGS: ARIA; Cardax, Inc. OTCQB: CDXI; and CareDx, Inc. (NASDAQ: CDNA). He holds a B.S. in Engineering and B.A. in Business Administration from Rutgers University and continued his executive education at Harvard Business School.
Simon X. Benito

Simon X. Benito,自2003年12月以来一直在本公司的董事会任职,给我们董事会带来了常规的会计和金融培训和专业知识、丰富的上市公司董事会经验、医疗行业高级管理经验和重要的业界关系网。在退休之前,Benito先生曾有过成功、丰富的服务一些跨国公司的高级管理职位的职业生涯,包括在Merck公司的25年。他最近的职位包括Merck 疫苗部的高级副总裁、Merck-Medco Managed Care的副执行总裁、Merck Human Health(日本)的执行董事和副总裁。另外,他曾是英国(England)特许会计师协会的30年的会员一直到1999年退休。自2005年4月以来,他曾是一个公开上市的特种制药公司- DURECT的董事。


Simon X. Benito has served as a director since April 2005. Mr. Benito is currently a director and chairman of the Audit Committee of Inovio Pharmaceuticals Corporation, a biomedical company. From 1974 to 1999 Mr. Benito held various positions at Merck & Co Inc. including Senior Vice President, Vaccine Division from 1996 to 1999 Executive Vice President, Merck-Medco Managed Care from 1994 to 1996 and Executive Director and Vice President, Merck Human Health, Japan from 1986 to 1993. Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales from 1969 to 1999 until his retirement from Merck.
Simon X. Benito,自2003年12月以来一直在本公司的董事会任职,给我们董事会带来了常规的会计和金融培训和专业知识、丰富的上市公司董事会经验、医疗行业高级管理经验和重要的业界关系网。在退休之前,Benito先生曾有过成功、丰富的服务一些跨国公司的高级管理职位的职业生涯,包括在Merck公司的25年。他最近的职位包括Merck 疫苗部的高级副总裁、Merck-Medco Managed Care的副执行总裁、Merck Human Health(日本)的执行董事和副总裁。另外,他曾是英国(England)特许会计师协会的30年的会员一直到1999年退休。自2005年4月以来,他曾是一个公开上市的特种制药公司- DURECT的董事。
Simon X. Benito has served as a director since April 2005. Mr. Benito is currently a director and chairman of the Audit Committee of Inovio Pharmaceuticals Corporation, a biomedical company. From 1974 to 1999 Mr. Benito held various positions at Merck & Co Inc. including Senior Vice President, Vaccine Division from 1996 to 1999 Executive Vice President, Merck-Medco Managed Care from 1994 to 1996 and Executive Director and Vice President, Merck Human Health, Japan from 1986 to 1993. Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales from 1969 to 1999 until his retirement from Merck.
Avtar Dhillon

Avtar Dhillon,加入本公司的时候担任总裁及首席执行官,以及于2001年10月是一位董事;2009年6月1日-2009年10月6日期间,他担任本公司的董事长兼总裁;以及担任执行董事长一直到2011年8月1日。他曾担任2011年8月1日生效的非执行董事长一职,卸去执行董事长一职。在加入本公司之前,Dhillon博士曾在现为Lumira Capital 公司的北美主要的医疗风险投资机构之一-MDS Capital 公司工作,1998年7月任顾问,以及随后在1999年8月成为投资经理,2000年成为副总裁。1989年7月,Dhillon博士创立了一家医疗诊所,随后从事了超过12年的家庭医学。在1997年3月-1998年7月期间,他曾在一家在NASDAQ上市的生物技术公司- Cardiome制药担任顾问。Dhillon博士拥有英属哥伦比亚大学(University of British Columbia)的荣誉心理学学士学位以及医学博士学位。他还是一个公开上市的早期农业生物公司- Stevia First公司的董事长。他还在自2011年3月以来任OncoSec Medical公司的非执行董事长。


Avtar Dhillon has served as the Chairman of our Board since March 2011. Dr. Dhillon has held various leadership roles at Inovio Pharmaceuticals, Inc. formerly Inovio Biomedical Corporation (NASDAQ: INO), a DNA vaccine development company, since October 2001 including President and Chief Executive Officer from October 2001 to June 2009 President and Chairman from June 2009 until October 2009 Executive Chairman from October 2009 until August 2011 and Non-Executive Chairman from August 2011 to January 2019. Prior to joining Inovio, Dr. Dhillon was Vice President and Lead Fund Manager of MDS Capital Corp. (now Lumira Capital Corp.), a leading healthcare venture capital organization. In July 1989 Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over 12 years.
Avtar Dhillon,加入本公司的时候担任总裁及首席执行官,以及于2001年10月是一位董事;2009年6月1日-2009年10月6日期间,他担任本公司的董事长兼总裁;以及担任执行董事长一直到2011年8月1日。他曾担任2011年8月1日生效的非执行董事长一职,卸去执行董事长一职。在加入本公司之前,Dhillon博士曾在现为Lumira Capital 公司的北美主要的医疗风险投资机构之一-MDS Capital 公司工作,1998年7月任顾问,以及随后在1999年8月成为投资经理,2000年成为副总裁。1989年7月,Dhillon博士创立了一家医疗诊所,随后从事了超过12年的家庭医学。在1997年3月-1998年7月期间,他曾在一家在NASDAQ上市的生物技术公司- Cardiome制药担任顾问。Dhillon博士拥有英属哥伦比亚大学(University of British Columbia)的荣誉心理学学士学位以及医学博士学位。他还是一个公开上市的早期农业生物公司- Stevia First公司的董事长。他还在自2011年3月以来任OncoSec Medical公司的非执行董事长。
Avtar Dhillon has served as the Chairman of our Board since March 2011. Dr. Dhillon has held various leadership roles at Inovio Pharmaceuticals, Inc. formerly Inovio Biomedical Corporation (NASDAQ: INO), a DNA vaccine development company, since October 2001 including President and Chief Executive Officer from October 2001 to June 2009 President and Chairman from June 2009 until October 2009 Executive Chairman from October 2009 until August 2011 and Non-Executive Chairman from August 2011 to January 2019. Prior to joining Inovio, Dr. Dhillon was Vice President and Lead Fund Manager of MDS Capital Corp. (now Lumira Capital Corp.), a leading healthcare venture capital organization. In July 1989 Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over 12 years.
J. Joseph Kim

J. Joseph Kim ,于2009年6月加入本公司并担任首席执行官和董事,以及在2009年10月6日成为本公司的总裁。Kim博士是本公司(SynCon)疫苗技术平台的主要的设计师,他的领导是本公司发现、开发和运载DNA疫苗业务的中心。他在2000-2009年6月期间曾是VGX制药公司/VGX的联合创始人,以及是该公司的前总裁、首席执行官及董事。在加入VGX之前,他曾在Merck公司负责一些经美国食品药品管理局(FDA)批准的产品和发育疗法的制造和加工开发。这些产品包括经美国食品药品管理局(FDA)批准的肝炎疫苗和治疗艾滋病病毒/艾滋病(HIV/AIDS)的发育疗法。Kim博士曾出版超过100篇同侪审查的科学论文以及书籍章节,拥有许多专利,以及审理几个编辑委员会和评审委员会。2002年,他被技术评论杂志评为世界前100位年轻革新者之一,以及被侧重于最具活力的40岁以下的区域专业人士的杂志-费城(Philadelphia)商业杂志评为“40 under 40”。他还曾在2003年10月被选到50个最具影响力的男士的名单上,以及2006年在Details杂志的“Power Issue”上。2004年,Kim博士以及VGX被世界经济论坛(the World Economic Forum)选为30个科技先锋之一。另外,他还上了包括10人的领导团、科学家和在世界影响和变化前列的高管的国际新闻周刊(Newsweek International)的“谁是下一个”话题。在最近的2006年,他曾被一个全球经济论坛(World Economic Forum)的分支-全球青年领袖论坛(Forum of Young Global Leaders)提名为一个年轻的全球领袖。Kim博士基姆是50个国家175位高管中,40岁以下的公众人物和知识分子。他还曾在上过Forbes和the New Yorker以及许多其他媒体渠道的文章。他曾在麻省理工学院(MIT)受过经济、工程和生物科学培训,在那里他是美国参议院荣誉学者。他拥有Pennsylvania大学的生物化学工程博士学位,以及Wharton学院的金融工商管理学硕士学位。


J. Joseph Kim joined us as our Chief Executive Officer and a director on June 1 2009 and also became our President on October 6 2009. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. He previously developed vaccines for Merck & Co. An immunologist by training, Dr. Kim holds an MIT undergraduate degree, a Ph.D. in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015 Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on our breakthroughs and the pharmaceutical landscape. MIT’s Technology Review magazine called him "one of the world’s top innovators." Dr. Kim is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system.
J. Joseph Kim ,于2009年6月加入本公司并担任首席执行官和董事,以及在2009年10月6日成为本公司的总裁。Kim博士是本公司(SynCon)疫苗技术平台的主要的设计师,他的领导是本公司发现、开发和运载DNA疫苗业务的中心。他在2000-2009年6月期间曾是VGX制药公司/VGX的联合创始人,以及是该公司的前总裁、首席执行官及董事。在加入VGX之前,他曾在Merck公司负责一些经美国食品药品管理局(FDA)批准的产品和发育疗法的制造和加工开发。这些产品包括经美国食品药品管理局(FDA)批准的肝炎疫苗和治疗艾滋病病毒/艾滋病(HIV/AIDS)的发育疗法。Kim博士曾出版超过100篇同侪审查的科学论文以及书籍章节,拥有许多专利,以及审理几个编辑委员会和评审委员会。2002年,他被技术评论杂志评为世界前100位年轻革新者之一,以及被侧重于最具活力的40岁以下的区域专业人士的杂志-费城(Philadelphia)商业杂志评为“40 under 40”。他还曾在2003年10月被选到50个最具影响力的男士的名单上,以及2006年在Details杂志的“Power Issue”上。2004年,Kim博士以及VGX被世界经济论坛(the World Economic Forum)选为30个科技先锋之一。另外,他还上了包括10人的领导团、科学家和在世界影响和变化前列的高管的国际新闻周刊(Newsweek International)的“谁是下一个”话题。在最近的2006年,他曾被一个全球经济论坛(World Economic Forum)的分支-全球青年领袖论坛(Forum of Young Global Leaders)提名为一个年轻的全球领袖。Kim博士基姆是50个国家175位高管中,40岁以下的公众人物和知识分子。他还曾在上过Forbes和the New Yorker以及许多其他媒体渠道的文章。他曾在麻省理工学院(MIT)受过经济、工程和生物科学培训,在那里他是美国参议院荣誉学者。他拥有Pennsylvania大学的生物化学工程博士学位,以及Wharton学院的金融工商管理学硕士学位。
J. Joseph Kim joined us as our Chief Executive Officer and a director on June 1 2009 and also became our President on October 6 2009. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. He previously developed vaccines for Merck & Co. An immunologist by training, Dr. Kim holds an MIT undergraduate degree, a Ph.D. in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015 Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on our breakthroughs and the pharmaceutical landscape. MIT’s Technology Review magazine called him "one of the world’s top innovators." Dr. Kim is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system.
Morton Collins

Morton Collins,自2009年6月1日以来一直在本公司的董事会任职。Collins博士此前在2008年6月-2009年6月期间是VGX公司的董事。自2003年8月以来,他一直是他所创立的Battelle Ventures公司的经营合伙人。在过去的40年里,Collins博士作为一位5个不同基金(Data Science Ventures I、 II、 III、 IV 以及Cardinal Partners)的创始人和经营合伙人,收获了广泛的早期高科技公司创投资金专业知识。他曾主持里根(Reagan)总统的Task Force的创业和创新,以及曾是George H. W. Bush总统的技术政策顾问。他是美国风险投资协会(National Venture Capital Association)的前总裁、董事以及董事长,目前在Kopin公司以及若干私营企业任董事。Collins拥有Delaware大学的工程学学士学位,以及Princeton大学的工程学硕士和博士学位。


Morton Collins was previously a director of VGX from June 2008 to June 2009. Dr. Collins has been the Managing Partner of Battelle Ventures, which he founded, since August 2003. For the past 40 years, Dr. Collins has acquired broad expertise in venture capital funding of early-stage high-technology companies as a founder and managing partner of five different funds, Battelle Ventures and Data Science Ventures I, II, III, and IV. Dr. Collins chaired President Reagan’s Task Force on Innovation and Entrepreneurship and served as technology policy advisor to President George H. W. Bush. He is a former President, Director and Chairman of the National Venture Capital Association, and currently serves as a Director of Kopin Corporation and several private companies. Dr. Collins holds a B.S. in Engineering and a Ph.D. in Science from the University of Delaware, and an M.A. and Ph.D. in Engineering from Princeton University.
Morton Collins,自2009年6月1日以来一直在本公司的董事会任职。Collins博士此前在2008年6月-2009年6月期间是VGX公司的董事。自2003年8月以来,他一直是他所创立的Battelle Ventures公司的经营合伙人。在过去的40年里,Collins博士作为一位5个不同基金(Data Science Ventures I、 II、 III、 IV 以及Cardinal Partners)的创始人和经营合伙人,收获了广泛的早期高科技公司创投资金专业知识。他曾主持里根(Reagan)总统的Task Force的创业和创新,以及曾是George H. W. Bush总统的技术政策顾问。他是美国风险投资协会(National Venture Capital Association)的前总裁、董事以及董事长,目前在Kopin公司以及若干私营企业任董事。Collins拥有Delaware大学的工程学学士学位,以及Princeton大学的工程学硕士和博士学位。
Morton Collins was previously a director of VGX from June 2008 to June 2009. Dr. Collins has been the Managing Partner of Battelle Ventures, which he founded, since August 2003. For the past 40 years, Dr. Collins has acquired broad expertise in venture capital funding of early-stage high-technology companies as a founder and managing partner of five different funds, Battelle Ventures and Data Science Ventures I, II, III, and IV. Dr. Collins chaired President Reagan’s Task Force on Innovation and Entrepreneurship and served as technology policy advisor to President George H. W. Bush. He is a former President, Director and Chairman of the National Venture Capital Association, and currently serves as a Director of Kopin Corporation and several private companies. Dr. Collins holds a B.S. in Engineering and a Ph.D. in Science from the University of Delaware, and an M.A. and Ph.D. in Engineering from Princeton University.
Adel A. F. Mahmoud

Adel A. F. Mahmoud,医学博士,哲学博士,自2011年6月担任GenVec 公司主管。 Dr. Mahmoud是提名与运营管理委员会成员。 Dr. Mahmoud自2007年是普林斯顿大学的化学生物系和 Woodrow Wilson 公共与国际关系事务学院的教授。在2006年他从首席医疗、疫苗、传染疾病顾问和Merck & Co制药公司管理委员会成员的职位上退休。从1999年至2005年他担任Merck Vaccines总裁和Merck & Co管理委员会成员。Dr. Mahmoud 目前担任 Becton, Dickinson公司和Sanaria有限公司、Inovio制药有限公司的董事。他还担任许多董事的科学顾问,健康蓝丝带国家协会座谈小组董事长,为波士顿大学医疗中心国家紧急传染疾病实验室和国家预防和扩散生化武器科学院委员会担任顾问。


Adel A. F. Mahmoud is a Professor at The Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University. He has recently retired as President of Merck Vaccines and member of Management Committee of Merck & Company, Inc. His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998. Dr. Mahmoud’s academic pursuits focused on investigations of the biology and function of eosinophils particularly in host resistance to helminthic infections as well as determinants of infection and disease in human schistosomiasis and other infectious agents. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006 including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. Dr. Mahmoud’s leadership in setting strategies for Global Health shaped the agenda of the Forum on Microbial Threats of the Institute of Medicine in recent years by tackling topical issues such as biological threats and bioterrorism; SARS; Pandemic Flu and others. He is an active contributor to scientific literature and authored and edited several textbooks and reports. Dr. Mahmoud received his M.D. degree from the University of Cairo in 1963 and Ph.D from the University of London, School of Hygiene and Tropical Medicine in 1971. He was elected to membership of the American Society for Clinical Investigation in 1978 the Association of American Physicians in 1980 and the Institute of Medicine of the National Academy of Sciences in 1987. He received the Bailey K. Ashford Award of the American Society of Tropical Medicine and Hygiene in 1983 and the Squibb Award of the Infectious Diseases Society of America in 1984. Dr. Mahmoud is a fellow of the American College of Physicians. He served on the National Advisory Allergy and Infectious Diseases Council and is a past president of the Central Society for Clinical Research and the International Society for Infectious Diseases. He currently serves as member of the Board of IAVI and as Chair of the Board of IVI in Seoul.
Adel A. F. Mahmoud,医学博士,哲学博士,自2011年6月担任GenVec 公司主管。 Dr. Mahmoud是提名与运营管理委员会成员。 Dr. Mahmoud自2007年是普林斯顿大学的化学生物系和 Woodrow Wilson 公共与国际关系事务学院的教授。在2006年他从首席医疗、疫苗、传染疾病顾问和Merck & Co制药公司管理委员会成员的职位上退休。从1999年至2005年他担任Merck Vaccines总裁和Merck & Co管理委员会成员。Dr. Mahmoud 目前担任 Becton, Dickinson公司和Sanaria有限公司、Inovio制药有限公司的董事。他还担任许多董事的科学顾问,健康蓝丝带国家协会座谈小组董事长,为波士顿大学医疗中心国家紧急传染疾病实验室和国家预防和扩散生化武器科学院委员会担任顾问。
Adel A. F. Mahmoud is a Professor at The Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University. He has recently retired as President of Merck Vaccines and member of Management Committee of Merck & Company, Inc. His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998. Dr. Mahmoud’s academic pursuits focused on investigations of the biology and function of eosinophils particularly in host resistance to helminthic infections as well as determinants of infection and disease in human schistosomiasis and other infectious agents. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006 including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. Dr. Mahmoud’s leadership in setting strategies for Global Health shaped the agenda of the Forum on Microbial Threats of the Institute of Medicine in recent years by tackling topical issues such as biological threats and bioterrorism; SARS; Pandemic Flu and others. He is an active contributor to scientific literature and authored and edited several textbooks and reports. Dr. Mahmoud received his M.D. degree from the University of Cairo in 1963 and Ph.D from the University of London, School of Hygiene and Tropical Medicine in 1971. He was elected to membership of the American Society for Clinical Investigation in 1978 the Association of American Physicians in 1980 and the Institute of Medicine of the National Academy of Sciences in 1987. He received the Bailey K. Ashford Award of the American Society of Tropical Medicine and Hygiene in 1983 and the Squibb Award of the Infectious Diseases Society of America in 1984. Dr. Mahmoud is a fellow of the American College of Physicians. He served on the National Advisory Allergy and Infectious Diseases Council and is a past president of the Central Society for Clinical Research and the International Society for Infectious Diseases. He currently serves as member of the Board of IAVI and as Chair of the Board of IVI in Seoul.
Angel Cabrera

Angel Cabrera,于2012年6月加入本公司董事会。他目前是弗吉尼亚(Virginia)最大的公立大学- George Mason大学的校长。此前,他曾是被广泛称为是世界领先的国际商务研究生学校- Thunderbird全球管理学院的校长。在Thunderbird之前,他曾在欧洲(Europe)高等商业学校之一- 马德里(Madrid)IE商学院任院长。在IE之前,他曾是Accenture的一位变更管理顾问。他是在Georgia 理工学院获得他的哲学博士学位以及心理学和认知科学硕士学位,在那里他曾是一位Fulbright学者;以及在马德里(Madri)的理工大学(Polytechnic University)获得他的计算机和电气工程学士学位和硕士学位。他曾获得来自世界经济论坛(World Economic Forum)、the Aspen研究所、华盛顿商报(the Washington Business Journal)、商业周刊(Business Week)和英国金融时报(the Financial Times)的若干领袖认可。他的丰富的行业出版包括从学习技术到心理学,管理和高等教育,其中包括一本最近出版的书:“走向全球化:如何在一个变革了的师姐中思考、行动和领导” Cabrera博士是企业社会责任和管理职业化的提倡者。他目前在PetSmart(PETM)的董事会任职。


Angel Cabrera, Ph.D. joined our Board in June 2012 ,Dr. Cabrera is currently President of George Mason University, the largest research university in Virginia. Previously he led two internationally renowned business schools: Thunderbird School of Global Management in Arizona and IE Business School in Madrid. Prior to IE he was a change management consultant with Accenture. Dr. Cabrera earned his Ph.D. and M.S. in psychology and cognitive science from the Georgia Institute of Technology-which he attended as a Fulbright Scholar-and his B.S. and M.S. in computer and electrical engineering from Madrid’s Polytechnic University. He has received several leadership recognitions from the World Economic Forum, the Aspen Institute, Business Week and other media. His publications in management, leadership, psychology and higher education have been cited over 2,500 times. Dr. Cabrera is an advocate of corporate social responsibility and managerial professionalism. He serves on the board of directors of the Federal Reserve Bank of Richmond and several non-profit and academic boards, including Georgia Tech, and has served on the boards of two other public companies.
Angel Cabrera,于2012年6月加入本公司董事会。他目前是弗吉尼亚(Virginia)最大的公立大学- George Mason大学的校长。此前,他曾是被广泛称为是世界领先的国际商务研究生学校- Thunderbird全球管理学院的校长。在Thunderbird之前,他曾在欧洲(Europe)高等商业学校之一- 马德里(Madrid)IE商学院任院长。在IE之前,他曾是Accenture的一位变更管理顾问。他是在Georgia 理工学院获得他的哲学博士学位以及心理学和认知科学硕士学位,在那里他曾是一位Fulbright学者;以及在马德里(Madri)的理工大学(Polytechnic University)获得他的计算机和电气工程学士学位和硕士学位。他曾获得来自世界经济论坛(World Economic Forum)、the Aspen研究所、华盛顿商报(the Washington Business Journal)、商业周刊(Business Week)和英国金融时报(the Financial Times)的若干领袖认可。他的丰富的行业出版包括从学习技术到心理学,管理和高等教育,其中包括一本最近出版的书:“走向全球化:如何在一个变革了的师姐中思考、行动和领导” Cabrera博士是企业社会责任和管理职业化的提倡者。他目前在PetSmart(PETM)的董事会任职。
Angel Cabrera, Ph.D. joined our Board in June 2012 ,Dr. Cabrera is currently President of George Mason University, the largest research university in Virginia. Previously he led two internationally renowned business schools: Thunderbird School of Global Management in Arizona and IE Business School in Madrid. Prior to IE he was a change management consultant with Accenture. Dr. Cabrera earned his Ph.D. and M.S. in psychology and cognitive science from the Georgia Institute of Technology-which he attended as a Fulbright Scholar-and his B.S. and M.S. in computer and electrical engineering from Madrid’s Polytechnic University. He has received several leadership recognitions from the World Economic Forum, the Aspen Institute, Business Week and other media. His publications in management, leadership, psychology and higher education have been cited over 2,500 times. Dr. Cabrera is an advocate of corporate social responsibility and managerial professionalism. He serves on the board of directors of the Federal Reserve Bank of Richmond and several non-profit and academic boards, including Georgia Tech, and has served on the boards of two other public companies.

高管简历

中英对照 |  中文 |  英文
J. Joseph Kim

J. Joseph Kim ,于2009年6月加入本公司并担任首席执行官和董事,以及在2009年10月6日成为本公司的总裁。Kim博士是本公司(SynCon)疫苗技术平台的主要的设计师,他的领导是本公司发现、开发和运载DNA疫苗业务的中心。他在2000-2009年6月期间曾是VGX制药公司/VGX的联合创始人,以及是该公司的前总裁、首席执行官及董事。在加入VGX之前,他曾在Merck公司负责一些经美国食品药品管理局(FDA)批准的产品和发育疗法的制造和加工开发。这些产品包括经美国食品药品管理局(FDA)批准的肝炎疫苗和治疗艾滋病病毒/艾滋病(HIV/AIDS)的发育疗法。Kim博士曾出版超过100篇同侪审查的科学论文以及书籍章节,拥有许多专利,以及审理几个编辑委员会和评审委员会。2002年,他被技术评论杂志评为世界前100位年轻革新者之一,以及被侧重于最具活力的40岁以下的区域专业人士的杂志-费城(Philadelphia)商业杂志评为“40 under 40”。他还曾在2003年10月被选到50个最具影响力的男士的名单上,以及2006年在Details杂志的“Power Issue”上。2004年,Kim博士以及VGX被世界经济论坛(the World Economic Forum)选为30个科技先锋之一。另外,他还上了包括10人的领导团、科学家和在世界影响和变化前列的高管的国际新闻周刊(Newsweek International)的“谁是下一个”话题。在最近的2006年,他曾被一个全球经济论坛(World Economic Forum)的分支-全球青年领袖论坛(Forum of Young Global Leaders)提名为一个年轻的全球领袖。Kim博士基姆是50个国家175位高管中,40岁以下的公众人物和知识分子。他还曾在上过Forbes和the New Yorker以及许多其他媒体渠道的文章。他曾在麻省理工学院(MIT)受过经济、工程和生物科学培训,在那里他是美国参议院荣誉学者。他拥有Pennsylvania大学的生物化学工程博士学位,以及Wharton学院的金融工商管理学硕士学位。


J. Joseph Kim joined us as our Chief Executive Officer and a director on June 1 2009 and also became our President on October 6 2009. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. He previously developed vaccines for Merck & Co. An immunologist by training, Dr. Kim holds an MIT undergraduate degree, a Ph.D. in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015 Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on our breakthroughs and the pharmaceutical landscape. MIT’s Technology Review magazine called him "one of the world’s top innovators." Dr. Kim is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system.
J. Joseph Kim ,于2009年6月加入本公司并担任首席执行官和董事,以及在2009年10月6日成为本公司的总裁。Kim博士是本公司(SynCon)疫苗技术平台的主要的设计师,他的领导是本公司发现、开发和运载DNA疫苗业务的中心。他在2000-2009年6月期间曾是VGX制药公司/VGX的联合创始人,以及是该公司的前总裁、首席执行官及董事。在加入VGX之前,他曾在Merck公司负责一些经美国食品药品管理局(FDA)批准的产品和发育疗法的制造和加工开发。这些产品包括经美国食品药品管理局(FDA)批准的肝炎疫苗和治疗艾滋病病毒/艾滋病(HIV/AIDS)的发育疗法。Kim博士曾出版超过100篇同侪审查的科学论文以及书籍章节,拥有许多专利,以及审理几个编辑委员会和评审委员会。2002年,他被技术评论杂志评为世界前100位年轻革新者之一,以及被侧重于最具活力的40岁以下的区域专业人士的杂志-费城(Philadelphia)商业杂志评为“40 under 40”。他还曾在2003年10月被选到50个最具影响力的男士的名单上,以及2006年在Details杂志的“Power Issue”上。2004年,Kim博士以及VGX被世界经济论坛(the World Economic Forum)选为30个科技先锋之一。另外,他还上了包括10人的领导团、科学家和在世界影响和变化前列的高管的国际新闻周刊(Newsweek International)的“谁是下一个”话题。在最近的2006年,他曾被一个全球经济论坛(World Economic Forum)的分支-全球青年领袖论坛(Forum of Young Global Leaders)提名为一个年轻的全球领袖。Kim博士基姆是50个国家175位高管中,40岁以下的公众人物和知识分子。他还曾在上过Forbes和the New Yorker以及许多其他媒体渠道的文章。他曾在麻省理工学院(MIT)受过经济、工程和生物科学培训,在那里他是美国参议院荣誉学者。他拥有Pennsylvania大学的生物化学工程博士学位,以及Wharton学院的金融工商管理学硕士学位。
J. Joseph Kim joined us as our Chief Executive Officer and a director on June 1 2009 and also became our President on October 6 2009. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. He previously developed vaccines for Merck & Co. An immunologist by training, Dr. Kim holds an MIT undergraduate degree, a Ph.D. in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015 Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on our breakthroughs and the pharmaceutical landscape. MIT’s Technology Review magazine called him "one of the world’s top innovators." Dr. Kim is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system.
Peter D. Kies

Peter D. Kies,自2002年6月以来一直任本公司的财务总监。在加入本公司之前的15年,他在全方位发展的生物技术和高科技公司学习到了丰富的功能和战略管理专业知识,从首次公开发行到盈利。在1996年5月到加入本公司之前,他曾在Newgen Results公司担任财务总监;在那之前,他曾在Cytel公司担任财务总监,以及在Ernst & Young律师事务所担任审计师。他拥有加州(California)圣地亚哥市(San Diego)的美国国际大学(United States International University)的工商管理学士学位。


Peter D. Kies,From May 1996 until joining us, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as an auditor for Ernst & Young LLP. Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.
Peter D. Kies,自2002年6月以来一直任本公司的财务总监。在加入本公司之前的15年,他在全方位发展的生物技术和高科技公司学习到了丰富的功能和战略管理专业知识,从首次公开发行到盈利。在1996年5月到加入本公司之前,他曾在Newgen Results公司担任财务总监;在那之前,他曾在Cytel公司担任财务总监,以及在Ernst & Young律师事务所担任审计师。他拥有加州(California)圣地亚哥市(San Diego)的美国国际大学(United States International University)的工商管理学士学位。
Peter D. Kies,From May 1996 until joining us, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as an auditor for Ernst & Young LLP. Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.
Niranjan Y. Sardesai

Niranjan Y. Sardesai,于2006年加入VGX制药公司担任副总裁(VP),以及于2007年被提升到高级研发副总裁(SVP R&D)。随着2009年6月VGX和Inovio的合并,他成为了该合并公司的高级研发副总裁(SVP R&D)。2012年1月,Sardesai博士被任命为本公司的首席运营官。在他的提升后的职位上,他负责该公司的企业和业务发展,以及主管这该公司的感染疾病和癌症疫苗以及疫苗运载系统的产品开发计划。他目前在一个传染病研究所/美国国家卫生研究院担任PI,负责艾滋病病毒(HIV)疫苗的开发,以及一个疟疾疫苗的开发计划的PI。在加入VGX之前,他曾是一个专注于企业生命科学公司的战略咨询公司- NVision咨询公司的创始人和总裁;以及曾在Fujirebio Diagnostics公司担任研发(R&D)总监。在Fujirebio的时候,他监管这研发和肿瘤组合扩大。他管理的产品开发,包括mesothelioma MESOMARK的新产品上市试验,膀胱癌以及卵巢癌的多重标机测试。他已经出版了超过40多个同行评审的出版物,出席过超过75场邀请去的讲座和演讲,以及申报了多项专利。Sardesai博士是在加州理工大学(California Institute of Technology)获得的化学博士学位,以及Pennsylvania大学Wharton学院获得的工商管理学硕士学位,并且在那里他还曾是Shils-Zeidman创业奖的获得者。他是在Scripps研究所和麻省理工学院(Massachusetts Institute of Technology)完成他的研究生学习的。他是在Indian理工大学Bombay分校获得他的化学学士学位和硕士学位的。


Niranjan Y. Sardesai is serving as our Chief Operating Officer since January 2012 overseeing the company’s corporate and business development, product development, and commercial functions as well as engineering, manufacturing, and quality operations. In 2016 he was appointed the President and CEO of Geneos Therapeutics, a 100 owned subsidiary of Inovio Pharmaceuticals which was created to focus on the development of patient specific neo-antigen targeted personalized immunotherapies. Prior to his appointment as our COO, Dr. Sardesai served as our Senior Vice President of Research and Development following the June 2009 merger with VGX Pharmaceuticals, at which company he held the same position. Dr. Sardesai joined VGX Pharmaceuticals in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. Across VGX and Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of our pipeline products to secure major licensing deals with big pharma companies. He has raised over $150 MM in non-dilutive grants and contract funding from government and non-government organizations and served as Principal Investigator on multi-institutional programs developing our oncology and infectious disease products. Under his leadership, our development stage products have been recognized by several pharmaceutical industry awards for innovation and the potential to address significant unmet needs. Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma MESOMARK, bladder cancer and a multi-marker test for ovarian cancer. Dr. Sardesai received a Ph.D. in Chemistry from the California Institute of Technology and an MBA entrepreneurship and finance from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. He has authored over 120+ peer-reviewed manuscripts and book chapters with particular contributions in vaccines and immunotherapies, oncology, and medical devices; presented at over 120+ invited lectures and presentations, and filed several patents. Dr. Sardesai was recently recognized by Pharmavoice magazine as one of the top 100 most influential and inspirational leaders from across the life sciences and healthcare industry -2015.
Niranjan Y. Sardesai,于2006年加入VGX制药公司担任副总裁(VP),以及于2007年被提升到高级研发副总裁(SVP R&D)。随着2009年6月VGX和Inovio的合并,他成为了该合并公司的高级研发副总裁(SVP R&D)。2012年1月,Sardesai博士被任命为本公司的首席运营官。在他的提升后的职位上,他负责该公司的企业和业务发展,以及主管这该公司的感染疾病和癌症疫苗以及疫苗运载系统的产品开发计划。他目前在一个传染病研究所/美国国家卫生研究院担任PI,负责艾滋病病毒(HIV)疫苗的开发,以及一个疟疾疫苗的开发计划的PI。在加入VGX之前,他曾是一个专注于企业生命科学公司的战略咨询公司- NVision咨询公司的创始人和总裁;以及曾在Fujirebio Diagnostics公司担任研发(R&D)总监。在Fujirebio的时候,他监管这研发和肿瘤组合扩大。他管理的产品开发,包括mesothelioma MESOMARK的新产品上市试验,膀胱癌以及卵巢癌的多重标机测试。他已经出版了超过40多个同行评审的出版物,出席过超过75场邀请去的讲座和演讲,以及申报了多项专利。Sardesai博士是在加州理工大学(California Institute of Technology)获得的化学博士学位,以及Pennsylvania大学Wharton学院获得的工商管理学硕士学位,并且在那里他还曾是Shils-Zeidman创业奖的获得者。他是在Scripps研究所和麻省理工学院(Massachusetts Institute of Technology)完成他的研究生学习的。他是在Indian理工大学Bombay分校获得他的化学学士学位和硕士学位的。
Niranjan Y. Sardesai is serving as our Chief Operating Officer since January 2012 overseeing the company’s corporate and business development, product development, and commercial functions as well as engineering, manufacturing, and quality operations. In 2016 he was appointed the President and CEO of Geneos Therapeutics, a 100 owned subsidiary of Inovio Pharmaceuticals which was created to focus on the development of patient specific neo-antigen targeted personalized immunotherapies. Prior to his appointment as our COO, Dr. Sardesai served as our Senior Vice President of Research and Development following the June 2009 merger with VGX Pharmaceuticals, at which company he held the same position. Dr. Sardesai joined VGX Pharmaceuticals in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. Across VGX and Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of our pipeline products to secure major licensing deals with big pharma companies. He has raised over $150 MM in non-dilutive grants and contract funding from government and non-government organizations and served as Principal Investigator on multi-institutional programs developing our oncology and infectious disease products. Under his leadership, our development stage products have been recognized by several pharmaceutical industry awards for innovation and the potential to address significant unmet needs. Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma MESOMARK, bladder cancer and a multi-marker test for ovarian cancer. Dr. Sardesai received a Ph.D. in Chemistry from the California Institute of Technology and an MBA entrepreneurship and finance from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. He has authored over 120+ peer-reviewed manuscripts and book chapters with particular contributions in vaccines and immunotherapies, oncology, and medical devices; presented at over 120+ invited lectures and presentations, and filed several patents. Dr. Sardesai was recently recognized by Pharmavoice magazine as one of the top 100 most influential and inspirational leaders from across the life sciences and healthcare industry -2015.
Mark L. Bagarazzi

Mark L. Bagarazzi,于2010年1月加入本公司并担任首席医务官。在加入Inovio之前,他曾是Merck公司的疫苗和生物制剂的全球监管事务主管。Bagarazzi博士主持Merck公司的带状疱疹的主要疫苗-带状疱疹疫苗疫苗产品和监管开发的进行,他曾负责与Merck相关的预防艾滋病病毒/艾滋病(HIV/AIDS)备用疫苗全球监管活动。他还曾成功地指导Merck公司的对抗轮状病毒的疫苗-RotaTeq疫苗的监管过程通过美国食品药品管理局(FDA)的批准。在2001年加入Merck公司之前,他曾是费城(Philadelphia)St. Christopher儿童医院的艾滋病病毒/艾滋病(HIV/AIDS)计划的董事。Bagarazzi博士曾是Drexel大学医学院的儿科助理教授。他是Pennsylvania大学医学院的疫苗和免疫疗法的客座讲师。此前,他曾是Johns Hopkins大学的一位客座讲师。他拥有好几项专利以及与别人合著了数十篇关注DNA疫苗课题的科学论文,这些论文都发表在同侪审查的医学期刊上。他拥有New Jersey理工大学以优异成绩获得的电气工程学士学位,以及New Jersey大学医学和牙科学的医学博士学位。


Mark L. Bagarazzi joined us as Chief Medical Officer in January 2010. Prior to joining us, Dr. Bagarazzi was Director of Worldwide Regulatory Affairs for vaccines and biologics at Merck & Co. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He successfully led the regulatory process through to FDA approval of RotaTeq®, Merck’s vaccine against rotavirus and was later responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. Prior to joining Merck in 2001 he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi was an assistant professor of pediatrics at Drexel College of Medicine and is a guest lecturer on vaccines and immunotherapeutics at the Perelman School of Medicine at the University of Pennsylvania. He was board certified in pediatrics and pediatric infectious diseases after completing a fellowship in pediatric infectious diseases at the Children’s Hospital of Philadelphia. He holds a BS in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from what is now known as Rutgers New Jersey Medical School.
Mark L. Bagarazzi,于2010年1月加入本公司并担任首席医务官。在加入Inovio之前,他曾是Merck公司的疫苗和生物制剂的全球监管事务主管。Bagarazzi博士主持Merck公司的带状疱疹的主要疫苗-带状疱疹疫苗疫苗产品和监管开发的进行,他曾负责与Merck相关的预防艾滋病病毒/艾滋病(HIV/AIDS)备用疫苗全球监管活动。他还曾成功地指导Merck公司的对抗轮状病毒的疫苗-RotaTeq疫苗的监管过程通过美国食品药品管理局(FDA)的批准。在2001年加入Merck公司之前,他曾是费城(Philadelphia)St. Christopher儿童医院的艾滋病病毒/艾滋病(HIV/AIDS)计划的董事。Bagarazzi博士曾是Drexel大学医学院的儿科助理教授。他是Pennsylvania大学医学院的疫苗和免疫疗法的客座讲师。此前,他曾是Johns Hopkins大学的一位客座讲师。他拥有好几项专利以及与别人合著了数十篇关注DNA疫苗课题的科学论文,这些论文都发表在同侪审查的医学期刊上。他拥有New Jersey理工大学以优异成绩获得的电气工程学士学位,以及New Jersey大学医学和牙科学的医学博士学位。
Mark L. Bagarazzi joined us as Chief Medical Officer in January 2010. Prior to joining us, Dr. Bagarazzi was Director of Worldwide Regulatory Affairs for vaccines and biologics at Merck & Co. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He successfully led the regulatory process through to FDA approval of RotaTeq®, Merck’s vaccine against rotavirus and was later responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. Prior to joining Merck in 2001 he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi was an assistant professor of pediatrics at Drexel College of Medicine and is a guest lecturer on vaccines and immunotherapeutics at the Perelman School of Medicine at the University of Pennsylvania. He was board certified in pediatrics and pediatric infectious diseases after completing a fellowship in pediatric infectious diseases at the Children’s Hospital of Philadelphia. He holds a BS in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from what is now known as Rutgers New Jersey Medical School.